TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15076943
Drug: Ganciclovir implant
Normalized name: ganciclovir Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir implant plus oral ganciclovir
Study: 9396394
Drug: CADO (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CADO (cyclophosphamide 300 mg/m2/d on days 1 to 5, vincristine 1.5 mg/m2/d on days 1 and 5, doxorubicin 60 mg/m2/d on day 5)
Study: 9396394
Drug: CVP (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVP (cisplatin 40 mg/m2/d and etoposide 100 mg/m2/d on days 1 to 5)
Study: 9396394
Drug: CADO/CVP (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CADO/CVP (combined treatment)
Study: 9396394
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of cisplatin
Study: 3285536
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (low doses of cyclosporine, azathioprine, and steroids)
Study: 3285536
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy (higher doses of cyclosporine plus steroids)
Study: 21877762
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (DEX group, n=21)
Study: 16501636
Drug: 10 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg G-CSF for 6 days after percutaneous coronary intervention
Study: 1510446
Drug: Netilmicin 5
Normalized name: netilmicin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 5 mg/kg once daily
Study: 1510446
Drug: Netilmicin 2
Normalized name: netilmicin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 2 mg/kg thrice daily
Study: 6649721
Drug: Running treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running treatment
Study: 9454384
Drug: Velocity, Intensity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velocity, Intensity, remainder of platelet aggregation induced by ADP 10 mcg/ml, 2.5 mcg/ml, 1.9 mcg/ml
Study: 8216397
Drug: cM‐T412 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM‐T412 50 mg
Study: 8216397
Drug: cM‐T412 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM‐T412 100 mg
Study: 8216397
Drug: cM‐T412 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM‐T412 10 mg
Study: 3688417
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine anesthesia
Study: 3688417
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical lidocaine anesthesia (Control)
Study: 29757876
Drug: Extended carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Extended carboplatin infusion (3-hour infusion)
Study: 29757876
Drug: Standard carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard carboplatin infusion (30-minute infusion)
Study: 22954201
Drug: Olmesartan/amlodipine (5/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/amlodipine (5/20 mg)
Study: 21680153
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 400mg once-daily
Study: 21680153
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800mg once-daily
Study: 21680153
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200mg once-daily
Study: 31732133
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus conventional treatment
Study: 26723196
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily until delivery
Study: 24228683
Drug: School hygiene
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School hygiene promotion and water treatment interventions and school sanitation improvements in schools with greater water availability
Study: 21190603
Drug: Total saponins
Normalized name: zingiberensis saponin I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total saponins of Panax notoginseng (PNS) extract Xueshuantong 0.45 g once a day for 2 months
Study: 21190603
Drug: Bailing capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing capsule of 1.0 g three times a day for 2 months
Study: 16823067
Drug: GM-CSF (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (150 microg subcutaneously once daily for 14 days after the second week of radiotherapy)
Study: 8923073
Drug: 10% low‐molecular‐weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low‐molecular‐weight HES solution (HES trauma, n = 14; HES sepsis; n = 14)
Study: 1558306
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) + Dextroamphetamine (0.09 mg/kg)
Study: 1558306
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) + Dextroamphetamine (0.18 mg/kg)
Study: 1558306
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) + Placebo Dextroamphetamine
Study: 1558306
Drug: Placebo Ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ethanol + Dextroamphetamine (0.09 mg/kg)
Study: 1558306
Drug: Placebo Ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Ethanol + Dextroamphetamine (0.18 mg/kg)
Study: 1558306
Drug: Ethanol +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol + Dextroamphetamine (low-dose)
Study: 1558306
Drug: Ethanol +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol + Dextroamphetamine (high-dose)
Study: 2936354
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg, 2 times daily)
Study: 2936354
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg, once daily)
Study: 25281044
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy using a fixed insulin dosing scheme
Study: 22721929
Drug: EDTA chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA chelation therapy for 3 months followed by as needed for 24 months
Study: 22721929
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 months followed by weekly for 5 weeks at 6-month intervals for 24 months
Study: 24987051
Drug: EDTA chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA chelation therapy
Study: 16340453
Drug: Alcohol (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.50 g ethanol/kg) drink
Study: 10525140
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) - 600 mg per day for 42 days
Study: 10525140
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (placebo) - 600 mg per day for 42 days
Study: 1646291
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 8 mg
Study: 31452417
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus fentanyl (0.05 mg/kg midazolam + 1.5 μg/kg fentanyl)
Study: 31452417
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus normal saline (0.05 mg/kg midazolam + 0.03 mL/kg normal saline)
Study: 27736246
Drug: 450 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/d green tea extract (GTE)
Study: 27736246
Drug: 450 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/d sour tea extract (STE)
Study: 27736246
Drug: 450 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/d maltodextrin (control)
Study: 23982033
Drug: β-blockers or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers or renin-angiotensin-aldosterone system blockers
Study: 21674183
Drug: Quad-helix treatment
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad-helix treatment
Study: 17552955
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously every 3 months for four treatments
Study: 10217590
Drug: Avaxim vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avaxim vaccine (inactivated hepatitis A vaccine), administered in two doses six months apart.
Study: 7775263
Drug: CPT‐11 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 60 mg/m2
Study: 7775263
Drug: CPT‐11 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 80 mg/m2 with granulocyte colony-stimulating factor support (2 micrograms/kg x 16 days)
Study: 2184649
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg, 20 mg, 30 mg
Study: 28662137
Drug: Moderate-vigorous physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-vigorous physical activity (average daily minutes = 24.0±18.3)
Study: 28662137
Drug: Sedentary behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary behaviour (average daily minutes = 535.2±83.8)
Study: 28662137
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity frequency (average daily bouts ≥10 min = 0.64±0.74)
Study: 25909356
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg/elbasvir 50 mg (oral, once-daily for 12 weeks)
Study: 25909356
Drug: Placebo (deferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (deferred therapy)
Study: 25909356
Drug: Grazoprevir 100
Normalized name: grazoprevir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir 100 mg/elbasvir 50 mg
Study: 22814814
Drug: Ambrisentan therapy
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan therapy for 12 weeks
Study: 9432193
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing Noveon AA1 (10% w/w)
Study: 9432193
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing Methocel K4M (10% w/w)
Study: 9432193
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing Carbopol 974P (10% w/w)
Study: 28540411
Drug: 12‐month Assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐month Assertive Community Treatment (ACT) as part of integrated care
Study: 25732262
Drug: VISCODERM Pearls
Approvals — FDA: no, EMA: no, PMDA: no
Description: VISCODERM Pearls (dietary supplement) administered 2 times a day for 4 weeks
Study: 25732262
Drug: VISCODERM Pearls
Approvals — FDA: no, EMA: no, PMDA: no
Description: VISCODERM Pearls (dietary supplement)
Study: 22426799
Drug: Tongyan spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongyan spray
Study: 20032972
Drug: 75% ethanol
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% ethanol extract of black cohosh containing 1.4 mg of 23‐epi‐26‐deoxyactein
Study: 20032972
Drug: 75% ethanol
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% ethanol extract of black cohosh containing 2.8 mg of 23‐epi‐26‐deoxyactein
Study: 20032972
Drug: 75% ethanol
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [XS Wipe 75% Ethanol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% ethanol extract of black cohosh containing 5.6 mg of 23‐epi‐26‐deoxyactein
Study: 18338955
Drug: Tamsulosin, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin, 0.4 mg once daily (Group A)
Study: 18338955
Drug: No alpha(1)-blocker
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alpha(1)-blocker (Group B, control group)
Study: 15975174
Drug: Isolated soya
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated soya protein (ISP) containing 68 mg/d soy isoflavones (genistein, daidzein, equol)
Study: 1921739
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg oestriol (E3) vaginal suppository, administered twice weekly for 3 weeks, then weekly for 6 months
Study: 21457883
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 mg cetirizine (CET) and 120 mg pseudoephedrine (PSE)
Study: 8845685
Drug: Once-daily levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily levobunolol 0.5%
Study: 8845685
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% once-daily
Study: 27920515
Drug: ELOM-080 (3×300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELOM-080 (3×300 mg)
Study: 24285617
Drug: daily acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily acute intermittent hypoxia (dAIH)
Study: 24285617
Drug: daily normoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily normoxia (dSHAM)
Study: 22717153
Drug: Inulin supplementation
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin supplementation (0.2 g, 0.3 g, 0.4 g, 0.5 g, and 0.6 g from day 4 to 28)
Study: 20406355
Drug: Rough surface
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough surface with microthread implants (Hexplant)
Study: 20406355
Drug: Rough-surface implants
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface implants (TiUnite)
Study: 20406355
Drug: Hybrid surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid surface implants (Restore)
Study: 9931168
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antihypertensive drugs
Study: 9931168
Drug: Endothelium-independent dilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelium-independent dilation with combination treatment
Study: 7474028
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reminder call (TC) and satisfaction questionnaire
Study: 2193261
Drug: Topical intravaginal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intravaginal clindamycin phosphate (0.1%, 1.0%, and 2.0%)
Study: 2193261
Drug: Topical intravaginal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intravaginal clindamycin phosphate (1.0%)
Study: 471856
Drug: Domperidone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (5 mg i.v.)
Study: 471856
Drug: Domperidone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (5 mg i.v.) with apomorphine (0.25 mg i.v.)
Study: 23560810
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy starting immediately after discharge from the hospital
Study: 19037616
Drug: Voice exercise/behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice exercise/behavioral treatment
Study: 12624520
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2, d1) and 5-FU continuous infusion (200 mg/m2/d, d1-21, q3w)
Study: 10685722
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg/Indapamide 0.625 mg (Per/Ind)
Study: 2990329
Drug: 44 081
Normalized name: 4,4'-dinitrocarbanilide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 081 R.P. (0.2% solution, self-administered intranasally)
Study: 27658417
Drug: Continue full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue full dose DMARDs and taper biologic therapy by 50% (Group 1)
Study: 27658417
Drug: Taper both
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper both DMARDs and biologic therapy dose by 50% (Group 2)
Study: 27658417
Drug: Taper DMARDs
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper DMARDs by 50% and stop biologic therapy (Group 3)
Study: 27658417
Drug: Stop both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop both DMARDs and biologic therapy (Group 4)
Study: 27658417
Drug: Continue medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue medications without change (Group 5)
Study: 11834427
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.03 mU/kg/day)
Study: 10794845
Drug: ApoAI cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoAI cutoff value of 1.50 g/L
Study: 1488158
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation in total parenteral nutrition
Study: 1488158
Drug: Standard total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard total parenteral nutrition without glutamine
Study: 6702863
Drug: Thiazide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide treatment
Study: 6499703
Drug: Thiazide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide treatment in hypokalaemic participants
Study: 25304690
Drug: Probiotics and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics and/or synbiotics administration
Study: 16257098
Drug: Quarter dose
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter dose of ETEC vaccine
Study: 2646187
Drug: Intravaginal application
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal application of tablets containing 3 mg of prostaglandin E2
Study: 29902969
Drug: BIS-guided propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS-guided propofol administration (target range 40-60)
Study: 29902969
Drug: Weight-related propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-related propofol administration (2 mg/kg)
Study: 29902969
Drug: BIS-guided propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS-guided propofol administration
Study: 29902969
Drug: Weight-related propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-related propofol administration
Study: 26287881
Drug: LASIK with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASIK with concurrent high-fluence CXL
Study: 23442755
Drug: Low-dose progestin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose progestin treatment (2.5 mg/day norethisterone acetate)
Study: 23442755
Drug: Low-dose progestin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose progestin treatment
Study: 21394001
Drug: Basal infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal infusion of 0.1% ropivacaine (5 ml/h for 6 hours)
Study: 21394001
Drug: Repeated hourly
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated hourly bolus doses of 0.1% ropivacaine
Study: 21394001
Drug: Basal infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal infusion vs. bolus doses comparison
Study: 18349213
Drug: i.v. granisetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. granisetron 1 mg
Study: 9418686
Drug: No ovulation‐induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ovulation‐induction drugs (spontaneous group)
Study: 7516915
Drug: Cyclophosphamide 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 4 g/m2 plus G-CSF (5 or 10 micrograms/kg)
Study: 2963647
Drug: Mobilat ointment
Normalized name: Mobilan
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobilat ointment (active treatment)
Study: 22205355
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with an angiotensin-converting inhibitor and receptor blocker
Study: 22205355
Drug: Inhibitor alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor alone
Study: 22205355
Drug: Inhibitor-blocker treatment
Normalized name: ACE inhibitors and calcium channel blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor-blocker treatment
Study: 20452823
Drug: Pramipexole (0.125-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.125-1.0 mg three times per day)
Study: 18665164
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg m(‐2) two times daily on days 1‐14 every 3 weeks
Study: 18665164
Drug: S-1 40‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40‐60 mg two times daily according to body surface area on days 1‐28 every 6 weeks
Study: 15567880
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml)
Study: 12759654
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose multidetector CT (30 mA protocol)
Study: 12759654
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose multidetector CT (10 mA protocol)